The anti-oestrogen tamoxifen produces haemodilution in normal postmenopausal women

Journal of Internal Medicine

Volumn 242, Issue 5, 1997, Pages 383-388

  Grey, A B ^a   Evans, M C ^a   Kyle, C ^a   Reid, I R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Antineoplastic agents; Oestrogen antagonists; Water electrolyte balance

Indexed keywords

ALBUMIN; ANTIESTROGEN; CREATININE; ELECTROLYTE; HEMOGLOBIN; TAMOXIFEN; UREA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ERYTHROCYTE COUNT; ERYTHROCYTE VOLUME; FEMALE; HEADACHE; HEMATOCRIT; HEMODILUTION; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; LEUKOCYTE COUNT; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; VAGINA DISCHARGE;

EID: 0030732058     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1997.00227.x     Document Type: Article

References (19)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 1-15.
2. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC et al. Effects of tamoxifen on bone mineral content in postmenopausal women with breast cancer. N Engl J Med 1991; 326: 852-6.
3. Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991; 115: 860-64.
4. Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 1995; 80: 3191-5.
5. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Ames RW, Reid IR. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med 1995; 99: 636-11.
6. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 1993; 303: 435-7.
7. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Nat Cancer Inst 1993; 85: 1398-1406.
8. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC et al. Raloxifene (Ly1 39481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994; 93: 63-9.
9. Aitken JM, Lindsay R, Hart DM. The redistribution of body sodium in women on long-term estrogen therapy. Clin Sci Mol Med 1974; 47: 179-87.
10. Prince RL, Dick I, Devine A, Price RI, Gutteridge DH, Kerr D et al. The effects of menopause and age on calcitropic hormones: A cross-sectional study of 655 healthy women aged 35-90. J Bone Miner Res 1995; 10: 835-42.
11. Witten C, Bradbury JT. Hemodilution as a result of estrogen therapy. Estrogenic effects in the human female. Proc Soc Exp Biol Med 1951; 78: 626-9.
12. Tankersley CG, Nicholas WC, Deaver DR, Mikita D, Kenny WL. Estrogen replacement in middle-aged women: thermoregulatory responses to exercise in the heat. J Appl Physiol 1992; 73: 1238-45.
13. Love RR, Surawicz TS, Williams EC. Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy. Arch Int Med 1992; 152: 317-20.
14. Sorlie PD, Garcia-Palmieri MR, Costas Jr R, Havlik RJ. Hematocrit and risk of coronary heart disease: the Puerto Rico Heart Health Program. Am Heart J 1981; 101: 456-61.
15. Kannel WB, Anderson K, Wilson PWF. White blood cell count and cardiovascular disease. Insights from the Framingham study. JAMA 1992; 267: 1253-6.
16. Erikssen G, Thaulow E, Sandvik L, Stormorken H, Erikssen J. Hematocrit: a predictor of cardiovascular mortality? J Intern Med 1993; 234: 493-9.
17. Gagnon DR, Zhang T-J, Brand FN, Kannel WB. Hematocrit and the risk of cardiovascular disease - The Framingham study: a 34-year follow-up. Am Heart J 1994; 127: 674-82.
18. de Simone G, Deveraux RB, Chien S, Alderman MH, Atlas SA, Laragh JH. Relation of blood viscosity to demographic and physiologic variables and to cardiovascular risk factors in apparently normal adults. Circulation 1990; 81: 107-17.
19. Hellem AJ, Borchgrevnik CF, Ames SB. The role of red blood cells in hemostasis: the relation between hematocrit, bleeding time and platelet adhesiveness. Brit J Haematol 1961; 7: 42-50.